Published in Br J Cancer on January 01, 1987
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature (2015) 3.24
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol (2012) 2.58
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis (2003) 2.56
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res (2006) 1.88
Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol (2008) 1.59
Use of intravenous bisphosphonates in older women with breast cancer. Oncologist (2008) 1.55
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest (1997) 1.49
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest (1996) 1.44
Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res (2006) 1.42
Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer (2011) 1.38
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol (2012) 1.37
Animal models of cancer pain. Comp Med (2008) 1.35
Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer (2009) 1.29
Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol (2011) 1.27
Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer (2009) 1.25
The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) (2010) 1.25
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res (2011) 1.23
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future. Int J Clin Oncol (2008) 1.21
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer (1989) 1.21
Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer (2003) 1.20
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol (2006) 1.14
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer (2010) 1.11
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab (2013) 1.08
Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer (2003) 1.08
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett (2009) 1.07
Biochemical prediction of response of bone metastases to treatment. Br J Cancer (1988) 1.07
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer (1987) 1.06
Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer (2004) 1.04
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging (2004) 1.02
MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. Nat Commun (2015) 1.01
An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS (1999) 1.01
The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett (2011) 1.01
Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease. Eur Spine J (2007) 1.00
153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging (2004) 1.00
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis (2009) 0.99
Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res (2009) 0.98
Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res (2001) 0.98
Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol (2013) 0.98
Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.98
Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer (2005) 0.96
Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patients. Eur Spine J (2007) 0.96
Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PLoS One (2010) 0.96
An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS One (2012) 0.95
Treating bony metastases. BMJ (1991) 0.95
A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett (2013) 0.95
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist (2011) 0.94
Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer (2006) 0.93
Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients. Br J Cancer (1987) 0.93
Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat (2011) 0.93
Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer (1993) 0.91
Breast Cancer Cell Colonization of the Human Bone Marrow Adipose Tissue Niche. Neoplasia (2015) 0.90
Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One (2012) 0.90
Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One (2012) 0.89
Bilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cells. BMC Cancer (2010) 0.89
Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Mol Ther (2015) 0.88
MRI detection of early bone metastases in b16 mouse melanoma models. Clin Exp Metastasis (2005) 0.88
A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol (2010) 0.87
Far beyond the usual biomarkers in breast cancer: a review. J Cancer (2014) 0.87
A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer (2012) 0.87
Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clin Epidemiol (2013) 0.87
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers Prev (2013) 0.87
Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol (2012) 0.86
CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl (1992) 0.86
Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action. Br J Cancer (1988) 0.86
Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann Diagn Pathol (2010) 0.86
Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J Clin Invest (2002) 0.86
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics (2012) 0.85
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol (2004) 0.85
Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre. J Bone Oncol (2013) 0.85
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer (2009) 0.84
Parametric response mapping of CT images provides early detection of local bone loss in a rat model of osteoporosis. Bone (2012) 0.84
Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab (2006) 0.84
A primer of bone metastases management in breast cancer patients. Curr Oncol (2008) 0.84
Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res (2010) 0.84
Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer (2002) 0.83
Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.83
Prognostic factors and survival in metastatic breast cancer: A single institution experience. Rep Pract Oncol Radiother (2013) 0.82
Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep (2015) 0.82
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. J Clin Med (2014) 0.82
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus (2014) 0.82
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia (2008) 0.82
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer (2005) 0.82
Osteoprotegerin in breast cancer: beyond bone remodeling. Mol Cancer (2015) 0.82
The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer. BMC Cancer (2015) 0.81
Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med (1999) 0.81
Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med (2011) 0.81
Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database. BMJ Open (2014) 0.81
Lung cancer presenting as a metastasis to the carpal bones: a case report. J Med Case Rep (2012) 0.81
The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer. J Transl Med (2014) 0.80
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer (1957) 21.59
Value of bone scanning in neoplastic disease. Semin Nucl Med (1984) 2.35
Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) (1981) 2.14
Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat (1982) 1.81
Bone metastases and breast cancer. Cancer Treat Rev (1985) 1.67
Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev (1985) 1.65
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
A tabulated summary of the FDG PET literature. J Nucl Med (2001) 4.37
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70
Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys (1997) 3.17
Stress and relapse of breast cancer. BMJ (1989) 3.07
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer (1999) 2.89
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
Reconstitution of interleukin 2 with albumin for infusion. Lancet (1990) 2.37
The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol (2004) 2.31
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer (1996) 2.28
Who needs steroid receptor assays? Lancet (1989) 2.27
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg (1989) 2.23
Mental stress--induced myocardial ischemia and cardiac events. JAMA (1996) 2.20
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med (2001) 2.20
Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. Phys Med Biol (1994) 2.19
Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev (2008) 2.17
Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res (1986) 2.15
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer (2001) 2.14
Improved SPECT quantification using compensation for scattered photons. J Nucl Med (1984) 2.14
The skeletal metastatic complications of renal cell carcinoma. Int J Oncol (2001) 2.12
Performance characteristics of a whole-body PET scanner. J Nucl Med (1994) 2.08
Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol (1986) 2.07
Staging non-small cell lung cancer with whole-body PET. Radiology (1999) 2.07
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev (2004) 2.05
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Acute pulmonary embolism: artificial neural network approach for diagnosis. Radiology (1993) 1.96
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Bayesian reconstruction and use of anatomical a priori information for emission tomography. IEEE Trans Med Imaging (1996) 1.87
Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol (2008) 1.80
Pylorus-preserving pancreatoduodenectomy. A clinical and physiologic appraisal. Ann Surg (1986) 1.74
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer (1978) 1.71
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer (1996) 1.70
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer (1993) 1.68
Bone metastases and breast cancer. Cancer Treat Rev (1985) 1.67
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol (1998) 1.64
Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis (2000) 1.63
Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol (1983) 1.62
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol (1993) 1.62
Effect of age on the response of the left ventricular ejection fraction to exercise. N Engl J Med (1980) 1.61
Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. Circulation (1990) 1.61
Cardiac phantom evaluation of simultaneously acquired dual-isotope rest thallium-201/stress technetium-99m SPECT images. J Nucl Med (1993) 1.61
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet (1983) 1.61
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients? Clin Oncol (R Coll Radiol) (2010) 1.60
Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.59
Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol (1998) 1.59
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology (1997) 1.56
Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. Neurology (1993) 1.54
Adult age differences in the functional neuroanatomy of verbal recognition memory. Hum Brain Mapp (1999) 1.54
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology (1993) 1.53
Transcatheter embolisation to control severe bleeding in fungating breast cancer. Eur J Surg Oncol (1988) 1.53
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol (2011) 1.51
Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women. J Gerontol (1989) 1.51
Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) (2006) 1.50
Advanced breast cancer: use of resources and cost implications. Br J Cancer (1993) 1.48
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med (1993) 1.47
Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer (2003) 1.47
Gallium citrate Ga 67 imaging in patients with suspected inflammatory processes. Arch Surg (1975) 1.47
Inverse Monte Carlo as a unified reconstruction algorithm for ECT. J Nucl Med (1986) 1.46
Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer (1993) 1.45
Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med (1988) 1.44
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol (1993) 1.44
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer (2004) 1.44
An evaluation of lesion detectability with cone-beam, fanbeam and parallel-beam collimation in SPECT by continuous ROC study. J Nucl Med (1994) 1.43
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol) (1998) 1.43
Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol (2001) 1.43
Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Ann Thorac Surg (1998) 1.42
Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.42
Evaluation of revised criteria for ventilation-perfusion scintigraphy in patients with suspected pulmonary embolism. Radiology (1994) 1.42
Accuracy of diagnosis of coronary artery disease by radionuclide management of left ventricular function during rest and exercise. Circulation (1981) 1.41
Advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence Guideline 2009 - an opportunity missed. Clin Oncol (R Coll Radiol) (2009) 1.39
Effects of meal size and correction technique on gastric emptying time: studies with two tracers and opposed detectors. J Nucl Med (1980) 1.38
Myocardial perfusion and ventricular function measurements during total coronary artery occlusion in humans. A comparison with rest and exercise radionuclide studies. Circulation (1994) 1.38
Sex-related differences in the normal cardiac response to upright exercise. Circulation (1984) 1.37
Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Current criteria for patient selection and results. Ann Surg (1987) 1.37
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer (1981) 1.36
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer (1994) 1.35
Indium-111 labeled leukocytes in the evaluation of suspected abdominal abscesses. Am J Surg (1980) 1.35
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer (1991) 1.35
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend (1999) 1.32
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg (1995) 1.31
A new combined approach to the conservative treatment of early breast cancer. Surgery (1984) 1.30
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer (1998) 1.30
Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. Arch Intern Med (1997) 1.30
Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med (1994) 1.30